ClinicalTrials.gg
Active, not recruitingNCT05296746RIBOLARISUpdated May 14, 2026

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

A Phase 2 interventional study of Ribociclib (neoadjuvant) and Chemotherapy (adjuvant) in Breast Cancer Stage II, sponsored by SOLTI Breast Cancer Research Group. Active, not recruiting at 51 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by SOLTI Breast Cancer Research Group · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies testing ribociclib in Breast Neoplasms — 17 open to participants now, 31 under way, 8 of them phase 3. ribociclib · Breast Neoplasms.

Planned enrollment
6th of 70
1,100 · median 116
Started
2022
with 8 others
Phase 2
27 of 70
8 open now
Primary completion
2029-10
later than 23 of 30 live
Registered
45th of 70
by date
Lead sponsor
3 of 70
SOLTI Breast Cancer Research Group

Among the 70 studies testing ribociclib in Breast Neoplasms, this one is the 6th largest by planned enrollment, is one of 9 that started in 2022, is one of 27 in phase 2, reaches primary completion later than 23 of the 30 other live ones, and was the 45th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 70 studies testing ribociclib in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About ribociclib

ribociclib: first FDA approval 2017 (KISQALI), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing ribociclib in Breast Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, multicenter international trial in men and women with primary operable HR+/HER2-, ki67≥20%, grade 2 or 3 and stage II breast cancer to evaluate safety and long-term efficacy of a non-chemo treatment in patients biologically responders to neoadjuvant ribociclib and letrozole.

This study aims to evaluate whether chemotherapy could be avoided for initial high-risk clinicopathological breast cancer patients that are converted to low genomic risk assessed by Risk of Recurrence-low (ROR-low) at 6 months of letrozole - ribociclib neoadjuvant treatment by continuing with this treatment in adjuvant setting.

Read the detailed description

All patients will receive letrozole plus ribociclib as neoadjuvant therapy. Treatment will consist of six 28-days cycles of daily letrozole (2.5mg; continuous) and ribociclib (600 mg/day; 3 weeks ON and 1 week OFF). In pre-menopausal and men patients, monthly LHRH agonists will be added to letrozole and ribociclib, beginning at least two weeks before starting letrozole and ribociclib.

After finalization of neoadjuvant treatment, patients will undergo surgery. Surgery samples of the residual tumor tissue (or tumor bed if pathological complete response [pCR] is achieved) will be collected regardless of whether they completed full neoadjuvant treatment.

This is not a randomized study; therefore, adjuvant treatment will be decided according to centrally assessed ROR and pathological stage after surgery. Patients are considered responders if they achieve a pCR or have ypN0 and ROR ≤ 30 or ypN1mi (cancer the lymph node is > 0.2 mm but \< 2 mm) and ROR ≤ 20 or ypN1 and ROR ≤ 10. All patients with ypN0 and ROR > 30, ypN1mi and ROR > 20, ypN1 and ROR > 10 or ypN2-3 are considered non-responders. Patients who progress during neoadjuvant treatment with ribociclib will be considered non-responders.

If indicated, adjuvant radiotherapy will be performed after surgery in the responder group and after adjuvant chemotherapy in the non-responders group.

Patients considered as responders will continue on treatment after optimal recovery of surgery and radiotherapy if indicated. Treatment with ribociclib (400 mg/day; 3 weeks ON and 1 week OFF) in the adjuvant setting will be maintained for 30 months approximately corresponding to 33 cycles. Letrozole treatment duration must be of at least 5 years. Visits during ribociclib treatment will be scheduled every three cycles. At the end of ribociclib treatment, visits will be every 6 months until 5 years from last patient's surgery.

Patients considered as non-responders will be treated with standard chemotherapy regimens. Patients will continue treatment with ribociclib and letrozole after optimal recovery of adjuvant chemotherapy and radiotherapy if indicated. Treatment with ribociclib (400 mg/day; 3 weeks ON and 1 week OFF) in the adjuvant setting will be maintained for 30 months approximately corresponding to 33 cycles after adjuvant chemotherapy. Endocrine therapy treatment duration must be of at least 5 years. Visits during ribociclib treatment will be scheduled every three cycles. At the end of ribociclib treatment, visits will be every 6 months until 5 years from last patient's surgery.

During adjuvant treatment (both responders and non-responders), letrozole can be switched to another aromatase inhibirtor (AI). Tamoxifen is only permitted after the 30-day post ribociclib visit, according to investigator criteria. Maintaining suppression of ovarian function by luteinizing hormone releasing hormone (LHRH) agonists during adjuvant treatment is mandatory (if AI are taken)/ recommended (if tamoxifen is taken) in premenopausal and men patients unless there is unmanageable toxicity.

Adjuvant hormonal treatment of patients who progress during neoadjuvant Ribociclib will be at the investigator's discretion.

Blood samples for ctDNA will be collected at screening, C2D1, pre-surgery, post-surgery, and every 6 months during the adjuvant period. Blood samples will be also collected in case of recurrence.

The global end of the study is defined as the date when the last patient accomplishes 5 years of follow up after surgery. The total duration of the study is expected to be 32 months for enrollment, 3 years of adjuvant treatment (including 2.5 years of ribociclib treatment), and additional 2.5 years of follow-up.

03

Conditions studied

  • Breast Cancer Stage II

Browse trials for

Keywords

  • breast cancer
  • ribociclib
  • ROR score
  • chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed Form prior to any study-specific procedure. Patients must be willing and able to comply with the protocol for the duration of the study including scheduled visits, treatment plan, laboratory tests and other study procedures.

    Note: Candidate patients in France must be affiliated to a Social Security System (or equivalent)

  2. Male (≥18 years old) or pre-menopausal women (≥40 years old) or women. Premenopausal/male patients will receive LHRH agonists 2 weeks before C1D1 and during treatment. Post-menopausal status is defined as:

    1. Age ≥60 years or
    2. Age \<60 years and 12 months of amenorrhea plus follicle stimulating hormone (FSH) and plasma estradiol (E2) levels within post-menopausal range by local laboratory assessment or
    3. Prior bilateral oophorectomy (≥7 days prior to Day 1 of treatment).
  3. confirmed invasive breast carcinoma, confirmed by the local pathologist, with all the following characteristics:

    1. Clinical stage II (Seventh Edition of the AJCC) which includes cT1cN1cM0, cT2cN0cM0, cT2cN1cM0 and cT3cN0cM0.
    2. ER-positive/-negative according to the most recent ASCO/CAP guidelines assessed locally, tumor cells >10% ER staining, grade 2 or 3 breast cancer.
    3. Ki-67 index by local analysis of ≥20% on untreated tumor tissue and/or high genomic risk (defined by gene signature): Oncotype DX® RS ≥ 26, Mammaprint® = Risk of Recurrence High, Prosigna® ROR ≥ 60 or luminal B, or Endopredict® = Risk of Recurrence High.

    Note: Multifocal and multicentric tumors are permitted if they are considered clinical stage II according to Seventh Edition of the AJCC. of all lesions is not necessary.

  4. Breast cancer eligible for primary surgery.
  5. Available pre-treatment FFPE core (tru-cut) biopsy evaluable for PAM50 or possibility to obtain one. Minimal sample requirements are to have at least 1 tumor cylinder with a minimal tissue surface of 4 mm2 tissue, containing at least 10% tumor cells and having enough tissue to do at least 2 cuts of 10 μm each (the quality of the sample must be approved centrally prior to inclusion).
  6. Have an (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 14 days prior to the date of enrolment.
  7. Adequate hematological, renal and hepatic function, as follows:

    1. (ANC) ≥1.5 x 109/L
    2. count ≥100 x 109/L
    3. ≥10 g/dL
    4. Alkaline phosphatase (AP) ≤2.5x (ULN)
    5. Total \<ULN. Patients with known Gilbert syndrome may be enrolled with total bilirubin ≤3 x ULN or direct bilirubin ≤1.5 x ULN.
    6. (ALT) and aspartate aminotransferase (AST) \<2.5x ULN
    7. Serum creatinine ≤1.5 mg/dL or calculated ≥60 mL/min (Cockcroft-Gault Equation)
    8. Potassium, total calcium (corrected for serum albumin), magnesium, and sodium within institutional normal limits or corrected to within normal limits with supplements before first dose of study medication.

    Male participants:

  8. A male participant must agree to use a as detailed in Appendix 1 of this protocol during the chemotherapy period (only non-responder cohort) and for at least 21 days, corresponding to time needed to eliminate any study treatments plus an additional 120 days (a spermatogenesis cycle) after the last dose of chemotherapy and refrain from donating sperm during this period. After the end of trial treatment, patients should use effective contraception according to local guidelines.

    Female participants:

  9. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies (see Appendix 1):

    1. Not a woman of (WOCBP) as defined in Appendix 1 OR
    2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 1 during the treatment period and for at least 21 days (corresponding to time needed to eliminate any study treatments) plus 30 days (a menstruation cycle) for study treatments with risk of genotoxicity after the last dose of study treatment. After the end of trial treatment, patients should use effective contraception according to local guidelines.

Exclusion criteria

Exclusion Criteria:

  1. Any prior treatment for primary invasive breast cancer. Letrozole or other drugs used during the preservation of ovarian function are permitted if administered after baseline .
  2. Inoperable breast cancer.
  3. Patients with Stage I, III or IV breast cancer are not eligible. Baseline staging to document absence of disease is not required, however is recommended as determined by institutional practice (in patients where there may be a reasonable suspicion of advanced disease e.g., large tumors, clinically positive axillary lymph nodes, signs and symptoms). If performed, reports of these examinations must be available. Examination type for staging, i.e. X-ray, sonography, bone scan, CT, MRI, and/or PET-CT, is at the discretion of the investigator.
  4. Bilateral invasive breast cancer.
  5. Patients who have undergone sentinel lymph node biopsy prior to study treatment.
  6. Inability or unwillingness to swallow pills.
  7. Malabsorption syndrome or other condition that would interfere with enteric absorption of study drugs.
  8. Participation in a prior study within 30 days prior to enrolment or within 5 half-lives of the investigational product, whichever is longer.
  9. Patient with a score B or C.
  10. Patient has active cardiac disease or a history of cardiac dysfunction including any of the following:

    1. History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty or stenting) or symptomatic pericarditis within 12 months prior to screening.
    2. History of documented congestive heart failure ( functional classification III-IV).
    3. Documented cardiomyopathy.
    4. Patient has a (LVEF) \<50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO).
    5. cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g. bifascicular block, Mobitz type II and third-degree AV block).
    6. Long Syndrome or family history of idiopathic sudden death or congenital long QT syndrome or any of the following:
    7. Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure or history of clinically significant/symptomatic bradycardia.
    8. QTc >500 msec or conduction abnormality in the previous 12 months.
    9. On screening 12-lead , any of the following cardiac parameters: bradycardia (resting heart rate \<50), tachycardia (resting heart rate >90), or QTcF interval ≥450 msec (using Fridericia's correction).
    10. Uncontrolled hypertension (Systolic blood pressure >160 mmHg or \<90 mmHg and/or diastolic >100 mmHg).
  11. Active infection requiring intravenous (IV) antibiotics.
  12. Prior story of pneumonitis of any cause.
  13. Prior thromboembolic events not attributable to a clear trigger cause.
  14. Known (HIV) infection.
  15. Any other diseases, active or uncontrolled pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may compromise compliance with the protocol, that may affect the interpretation of the results, or renders the patients at high risk from treatment complications.
  16. Significant traumatic injury within 3 weeks prior to initiation of study treatment.
  17. Major surgical procedure (not including minor procedures such as lymph node biopsy, tumor core biopsy, fine needle aspiration or bilateral oophorectomy) within 3 weeks prior to initiation of study treatment or not fully recovered from any side effects of previous procedures.
  18. Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
  19. Patients with a history of any are ineligible except for the following circumstances:

    • Patients with a malignancy history other than invasive breast cancer are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy.
    • Patients with the following cancers are eligible, even if diagnosed and treated within the past 5 years: ductal carcinoma in situ of the breast, cervical cancer in situ, and non-metastatic non-melanomatous skin cancers.
  20. Estrogen replacement therapy stopped less than 2 weeks before treatment start.
  21. Known to any of the of ribociclib, letrozole, goserelin or decapapetyl (if men or pre-menopausal).
  22. within 30 days prior to the first dose of study.
  23. Patients currently on following medications, which cannot be interrupted 7 days prior treatment start:

    1. Any prohibited medication as per goserelin or decapapetyl (pre-menopasual patients), letrozole or ribociclib label
    2. Herbal preparations/medications, dietary supplements.
    3. Medications that have a known risk to prolong the QT interval or cause Torsades de Pointe.
    4. Medications with a narrow therapeutic window and predominantly metabolized through .
    5. Strong inhibitors of CYP3A4, including grapefruit, grapefruit hybrids, pummelos, star-fruit and Seville oranges.
    6. Strong inducers of CYP3A4.
    7. Warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin or fondaparinux is allowed.
  24. A who has a positive urine pregnancy test within 72 hours prior to allocation (see Appendix 1). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

    Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.

  25. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  26. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  27. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment. Males who want to father children should consider preserving the sperm before starting treatment with ribociclib.
  28. Persons deprived of their liberty or under protective custody or guardianship.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,100 participants (estimated)

Study arms

  • Experimental
    Responder (ROR-low)

    Ribociclib (400 mg/day; 3 weeks ON and 1 week OFF) in the adjuvant setting for 33 cycles. Letrozole or other aromatase inhibitor treatment duration must be of at least 5 years

    Drug: Ribociclib (neoadjuvant) · Drug: Ribociclib (adjuvant)

  • Other
    Non-responder (ROR-medium/high)

    Adjuvant chemotherapy. 3 regimens are permitted. Regimen 1: \- Doxorubicin 60 mg/m2 IV day 1 (or Epirubicin 75-100 mg/m2) and Cyclophosphamide 600-830 mg/m2 day 1 every 14/21 days for 4 cycles, followed by Paclitaxel 80 mg/m2 every week for 12 weeks or Docetaxel 75-100 mg/m2 every 3 weeks for 12 weeks. Regimen 2: \- Docetaxel 75-100 mg/m2 IV day 1 and Cyclophosphamide 600-830 mg/m2 day 1 every 21 days for 4-6 cycles. Regimen 3: \- Paclitaxel 80 mg/m2 every week for 12 weeks or Docetaxel 75-100 mg/m2 every 3 weeks for 12 weeks followed by Doxorubicin 60 mg/m2 IV day 1 (or Epirubicin 75-100 mg/m2) and Cyclophosphamide 600-830 mg/m2 day 1 every 14/21 days for 4 cycles. Then, patients will receive ribociclib (400 mg/day; 3 weeks ON and 1 week OFF) in the adjuvant setting for 33 cycles. Letrozole or other aromatase inhibitor treatment duration must be of at least 5 years

    Drug: Ribociclib (neoadjuvant) · Drug: Chemotherapy (adjuvant) · Drug: Ribociclib (adjuvant)

Interventions

06

What researchers measure

Primary outcomes

  1. Distant metastasis-free survival (DMFS) in the ROR-low cohort (responder cohort)

    DMFS is defined as the time from date of surgery to date of first event of distant metastatic recurrence or death (any cause).

    Time frame: Until recurrence (if it happens) for a maximum of 7.5 years of follow-up

Secondary outcomes

  1. Invasive disease-free survival (IDFS) in the ROR-low cohort (responder cohort)

    iDFS is defined as the time from surgery until the date of the first occurrence of one of the following events: recurrence of ipsilateral invasive breast tumor, recurrence of ipsilateral locoregional invasive disease, a distant disease recurrence, contralateral invasive breast cancer, second primary or death from any cause.

    Time frame: Until recurrence (if it happens) for a maximum of 7.5 years of follow-up

  2. Pathological complete response in breast and axillary lymph nodes (pCRBL)

    pCRBL after completion of study treatment, defined as the complete absence of invasive carcinoma in the breast and axillary lymph nodes on histological examination at the time of definitive surgery, irrespective of in situ carcinoma in the breast.

    Time frame: At surgery (after 6 months of neoadjuvant treatment)

  3. Residual Cancer Burden 0/1 (RCB0/1)

    RCB0/1 after neoadjuvant treatment, according to the MD Anderson Cancer Center procedures, as per local assessment.

    Time frame: At surgery (after 6 months of neoadjuvant treatment)

  4. Rate of ROR-low (at surgery) after neoadjuvant treatment.

    Rate of ROR-low (at surgery) after neoadjuvant treatment, according to Prosigna test.

    Time frame: At surgery (after 6 months of neoadjuvant treatment)

  5. Distant metastasis-free survival (DMFS) in the ROR-medium/high cohort (non-responder cohort)

    DMFS is defined as the time from date of surgery to date of first event of distant metastatic recurrence or death (any cause).

    Time frame: Until recurrence (if it happens) for a maximum of 7.5 years of follow-up

  6. Incidence, duration and severity of Adverse Events (AEs)

    Incidence, duration and severity of Adverse Events (AEs) assessed by the National Cancer Instirute (NCI) Common Terminology for Classification of Adverse Events (CTCAE) version 4.03, including dose reductions, delays and treatment discontinuations.

    Time frame: From ICF signature until the end of treatment visit

Other outcomes

  1. Correlation between DMFS and pCR

    Correlation between DMFS and pCR in ROR-low cohort, in ROR-medium/high cohort, and in all patients

    Time frame: Until recurrence (if it happens) for a maximum of 7.5 years of follow-up

  2. Correlation between DMFS and ROR score (as a continuous variable)

    Correlation between DMFS and ROR score (as a continuous variable) in ROR-low cohort, in ROR-medium/high cohort, and in all patients.

    Time frame: Until recurrence (if it happens) for a maximum of 7.5 years of follow-up

  3. Correlation between DMFS and RCB

    Correlation between DMFS and RCB at surgery in ROR-low cohort, in ROR-medium/high cohort, and in all patients

    Time frame: Until recurrence (if it happens) for a maximum of 7.5 years of follow-up

  4. Correlation between DMFS and PAM50 intrinsic breast cancer subtype at surgery

    Correlation between DMFS and PAM50 intrinsic breast cancer subtype at surgery in ROR-low cohort, in ROR-medium/high cohort, and in all patients

    Time frame: Until recurrence (if it happens) for a maximum of 7.5 years of follow-up

  5. Correlation between DMFS and PAM50 intrinsic breast cancer subtype at baseline

    Correlation between DMFS and PAM50 intrinsic breast cancer subtype at baseline in ROR-low cohort, in ROR-medium/high cohort, and in all patients

    Time frame: Until recurrence (if it happens) for a maximum of 7.5 years of follow-up

  6. To perform correlative studies based on ctDNA analysis.

    * To evaluate the predictive value of early dynamic changes in ctDNA between baseline and after 1 cycle of ribociclib + letrozole. * Correlation of clinical benefit endpoints and specific baseline genomic alterations or patterns in ctDNA. * To explore the value of ctDNA to detect a later clinical recurrence during the adjuvant phase. * To explore alterations or patterns related to drug resistance.

    Time frame: From ICF signature until recurrence

  7. To Evaluate plasma Thymidine Kinase 1 activity (TKa) over time as a proliferation blood marker and its association with clinical outcome.

    To correlate TKa dynamics with DMFS, IDFS, pCR and RCB0/1.

    Time frame: From ICF signature until recurrence

07

Study locations

51 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Oct 2029, 88 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 88 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2022
First posted
Mar 25, 2022
StartActual
May 3, 2022
Primary completionEst.
Oct 1, 2029
CompletionEst.
Dec 1, 2031
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05296746
Lead sponsor
SOLTI Breast Cancer Research Group
Collaborators
Novartis, UNICANCER
Responsible party
Sponsor
First posted
Mar 25, 2022
Start date
May 3, 2022
Primary completion
Oct 1, 2029 (estimated)
Completion
Dec 1, 2031 (estimated)
Last update
May 14, 2026

Study contacts

Aleix Prat, MD
principal investigator · Hospital Clínic de Barcelona/SOLTI
Paul Cottu, MD
principal investigator · Institut Curie Paris
Joaquín Gavilá, MD
principal investigator · Instituto Valenciano de Oncología
Thibault de La Motte Rouge, MD
principal investigator · Centre Eugène Marquis, Rennes

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribociclib

Start the discussion